Results 101 to 110 of about 127,348 (379)

Reduced CD40L expression on ex vivo activated CD4+T-lymphocytes from patients with excellent renal allograft function measured with a rapid whole blood flow cytometry procedure [PDF]

open access: yes, 2004
Background: The CD40-CD40L (CD154) costimulatory pathway plays a critical role in the pathogenesis of kidney allograft rejection. In renal transplant biopsies, CD4+ CD40L+ graft-infiltrating cells were detected during chronic rejection in contrast to ...
Friedrich, N.   +5 more
core   +1 more source

MYCOPHENOLATE MOFETIL TREATMENT REDUCES THE RISK OF TREATMENT ESCALATION DUE TO VASCULAR COMPLICATIONS IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: EMULATION OF A TARGET TRIAL FROM ITALIAN RHEUMATOLOGY SOCIETY SPRING REGISTRY

open access: yesArthritis Care &Research, Accepted Article.
Objective Mycophenolate Mofetil (MMF) use in limited cutaneous systemic sclerosis (lcSSc) is relatively uncommon due to the lower fibrotic burden and the predominance of the vascular complications. In vitro observations and clinical data from transplanted patients suggest a protective effect of MMF on endothelial function.
Enrico De Lorenzis   +77 more
wiley   +1 more source

Marked Long‐term Improvement in Lung Function in Melanoma Differentiation‐associated Protein 5 (MDA5) Antibody Positive Dermatomyositis Patients: Experience of a Single Center Longitudinal Cohort in North America

open access: yesArthritis Care &Research, Accepted Article.
Objective The objective of this study was to describe the longitudinal disease course and pulmonary outcomes of North American patients with melanoma differentiation‐associated gene 5 antibody (MDA5 ab) associated dermatomyositis (DM). Methods Thirty patients with MDA5 ab DM were identified in a single center longitudinal cohort of 352 patients with ...
Jenice X Cheah   +8 more
wiley   +1 more source

Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review.

open access: yesPLoS ONE, 2015
BackgroundMycophenolate is increasingly being used in the rheumatic diseases. Its main adverse effects are gastrointestinal, myelosuppression, and infection.
Mohammed A Omair   +2 more
doaj   +1 more source

For the eye altering, alters the all [PDF]

open access: yes, 2015
C
Boey, Olivier   +4 more
core   +1 more source

Loss of SOCS1 in Donor T Cells Exacerbates Intestinal GVHD by Driving a Chemokine‐Dependent Pro‐Inflammatory Immune Microenvironment

open access: yesAdvanced Science, EarlyView.
T cell‐specific Socs1 knockout leads to inflammatory differentiation of CD8+ T cells, prompting the STAT1/2 complex to drive the activation of Ccl5, Ccr5, and Cxcr3, and promoting the skewing of monocytes toward a pro‐inflammatory M1 macrophage lineage.
Zhigui Wu   +14 more
wiley   +1 more source

Idiopathic membranoproliferative glomerulonephritis treated with mycophenolate mofetil

open access: yesClinical Case Reports, 2018
Key Clinical Message “Idiopathic” membranoproliferative glomerulonephritis (MPGN) is rare compared to secondary forms and usually a progressive disease.
Abhilash Koratala   +3 more
doaj   +1 more source

Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials? [PDF]

open access: yes, 2010
OBJECTIVES: To obtain an objective, unbiased assessment of skin fibrosis in patients with SSc for use in clinical trials of SSc disease-modifying therapeutics.
Busquets, Joanna   +3 more
core   +3 more sources

Risk Factors for Small‐for‐Size Syndrome Grade B/C After Simultaneous Splenectomy in Adult Living‐Donor Liver Transplantation

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
In a single‐center cohort of 577 adult LDLT recipients who underwent simultaneous splenectomy, clinically significant SFSS grade B/C (ILTS‐iLDLT‐LTSI 2023) occurred in 18.2% and was associated with inferior graft survival. Multivariate analysis identified MELD ≥ 30, NLR ≥ 4.5, and donor age ≥ 50 years as independent risk factors, which risk rising ...
Kyohei Yugawa   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy